{"contentid": 488285, "importid": NaN, "name": "Long-term results on Oxbryta published in journal", "introduction": "US biopharma Global Blood Therapeutics has announced that The Lancet Haematology has published the complete analysis of 72-week data from the Phase III HOPE Study of Oxbryta (voxelotor) tablets in patients with sickle cell disease (SCD).", "content": "<p>US biopharma Global Blood Therapeutics (Nasdaq: GBT) has announced that The Lancet Haematology has published the complete analysis of 72-week data from the Phase III HOPE Study of Oxbryta (voxelotor) tablets in patients with sickle cell disease (SCD).</p>\n<p>The results showed significant and sustained improvement in hemoglobin levels, reduction in hemolysis and improved overall health status in patients treated with Oxbryta.</p>\n<p><span class=\"pullQuote\">\"The HOPE Study represents a significant milestone in advancing the treatment of SCD\"</span>These findings support the long-term use of Oxbryta to reduce hemolytic anemia and hemolysis in SCD, potentially mitigating life-threatening complications of the condition.</p>\n<p>Oxbryta, an oral, once-daily therapy that directly inhibits hemoglobin polymerization, the root cause of the sickling and destruction of red blood cells in SCD, is approved in the USA for the treatment of SCD in patients aged 12 years and older.</p>\n<p>Ted Love, president and chief executive of GBT, said: &ldquo;The SCD community, which for decades has been dramatically underserved, deserves treatments that address the sickling and destruction of red blood cells due to hemoglobin polymerization &ndash; the root cause of this disease.</p>\n<p>&ldquo;The HOPE Study represents a significant milestone in advancing the treatment of SCD, and we are building on this ground-breaking trial with our commitment to increase access to Oxbryta and develop novel therapeutics that can transform SCD into a well-managed disease.&rdquo;</p>\n<p>The European Medicines Agency has accepted for review the Marketing Authorization Application seeking full marketing authorization of Oxbryta in Europe to treat hemolytic anemia in SCD patients aged 12 years and older.</p>", "date": "2021-04-08 12:42:00", "meta_title": NaN, "meta_keywords": "Oxbryta, patients, published, HOPE, Study, blood, disease, therapeutics, results, significant, long-term, journal, Global, treatment, biopharma, sickle", "meta_description": "US biopharma Global Blood Therapeutics has announced that The Lancet Haematology has published the complete analysis of 72-week data from the Phase III HOPE Stu", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-08 12:37:38", "updated": "2021-04-08 14:15:39", "access": NaN, "url": "https://www.thepharmaletter.com/article/long-term-results-on-oxbryta-published-in-journal", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "gbt_global_blood_therapeutics_correct_large.jpg", "image2id": "gbt_global_blood_therapeutics_correct_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Hematology", "topic_tag": "Drug Trial, Research", "geography_tag": "USA", "company_tag": "Global Blood Therapeutics", "drug_tag": "Oxbryta", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-08 12:42:00"}